Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 5/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CALCA | P06881 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517727 | 0.90 | MEN1 (0.57) | KMT2AMEN1L3MBTL1CNR2CNR1 | |
| SCHEMBL16236331 | 0.88 | CNR2 (0.47) | KMT2AMEN1L3MBTL1CNR2CNR1 | |
| SCHEMBL16236659 | 0.86 | CNR2 (0.45) | KMT2AMEN1L3MBTL1CNR2CNR1 | |
| SCHEMBL16236986 | 0.86 | CNR2 (0.47) | KMT2AMEN1L3MBTL1CNR2CNR1 | |
| SCHEMBL3515850 | 0.82 | L3MBTL1 (0.54) | KMT2AMEN1L3MBTL1CNR2CNR1 | |
| SCHEMBL3519484 | 0.82 | CNR2 (0.46) | KMT2AMEN1CNR2CNR1TP53 | |
| SCHEMBL3517675 | 0.78 | CNR2 (0.47) | CNR2CNR1TP53MAPTSMN1; SMN2 | |
| SCHEMBL16236087 | 0.78 | CNR1 (0.70) | KMT2ACNR2CNR1SMN1; SMN2 | |
| SCHEMBL16236264 | 0.77 | TDP1 (0.58) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL19519829 | 0.77 | NPC1 (0.47) | KMT2AMEN1L3MBTL1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| WO-2008010964-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | KMT2A 2764/4885MEN1 3126/4885L3MBTL1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.